Caloric requirements in patients with renal insufficiency
نویسندگان
چکیده
منابع مشابه
Cefepime Neurotoxicity in Patients with Renal Insufficiency
Cefepime is a fourth-generation cephalosporin that is active against both gram-positive and gram-negative organisms. It is administered parenterally for the treatment of severe infections. Approximately 85% of the drug is excreted unchanged by the kidneys. Neurotoxicity in patients with renal failure who are treated with cefepime has been reported sporadically. We report on two senile patients ...
متن کاملCefmenoxime pharmacokinetics in patients with renal insufficiency.
The pharmacokinetics of cefmenoxime were determined after a 30-min intravenous infusion of 15 mg/kg of total body weight to 33 adult subjects with normal renal function (CLCR, greater than 80 ml/min per 1.73 m2, group I), mild renal insufficiency (CLCR, 40 to 79 ml/min per 1.73 m2, group II), moderate renal insufficiency (CLCR, 10 to 39 ml/min per 1.73 m2, group III), or severe renal impairment...
متن کاملIs metformin safe in patients with mild renal insufficiency?
Among the first million patients who received metformin in the U.S., 47 patients developed metforminassociated lactic acidosis (MALA), with 43 having predisposing factors for lactic acidosis (including moderate to severe renal failure and congestive heart failure) (1). Although there was initial concern, studies have suggested that MALA is secondary to underlying conditions and represents a coi...
متن کاملOBSERVATIONS Is Metformin Safe in Patients With Mild Renal Insufficiency?
Among the first million patients who received metformin in the U.S., 47 patients developed metforminassociated lactic acidosis (MALA), with 43 having predisposing factors for lactic acidosis (including moderate to severe renal failure and congestive heart failure) (1). Although there was initial concern, studies have suggested that MALA is secondary to underlying conditions and represents a coi...
متن کاملEndralazine in patients with severe hypertension and renal insufficiency.
Endralazine, a new peripheral vasodilator, was given in conjunction with a beta-blocker to 21 patients with hypertension and chronic renal failure. All subjects were either poorly controlled on their previous antihypertensive regime or were experiencing unacceptable adverse effects from drugs. After 4 weeks blood pressure was reduced in all patients and symptomatic side effects were few. Two pa...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nephrology Dialysis Transplantation
سال: 1996
ISSN: 1460-2385,0931-0509
DOI: 10.1093/ndt/11.9.1929